Physician profile
Michael M Hall
NPI 1245348382
$1,753.13
in general payments reported to CMS, 2019-2025
22 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $78.89 · 2021: $242 · 2022: $163 · 2023: $523 · 2024: $390 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080 · Education: $13.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.32 |
| Education | $13.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.67 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $201.00 | 2019-2024 | Evenity, Otezla, Repatha |
| Acumed LLC | $179.44 | 2025 | Acumed, Inframe Implant, Nanophix Implant |
| Stryker Corporation | $126.08 | 2021-2023 | Variax |
| Skeletal Dynamics INC | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $88.50 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $81.76 | 2023 | Belsomra, Steglatro |
| Integra Lifesciences Corporation | $62.75 | 2019-2023 | Integra, Integra Dermal Regeneration Template |
| Abbott Laboratories | $61.21 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $60.22 | 2023 | |
| Smith+Nephew, INC. | $49.47 | 2024 | N/A, Evos |
| Sanofi Pasteur INC. | $44.88 | 2019-2023 | |
| Lilly USA, LLC | $34.47 | 2022 | |
| Exact Sciences Corporation | $29.37 | 2023-2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $28.96 | 2023-2024 | Amvuttra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.86 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.65 | 2019-2023 | Xifaxan |
| Siemens Medical Solutions USA, INC. | $22.08 | 2023 | Embozene |
| Daiichi Sankyo INC. | $21.18 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.17 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.55 | 2023 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.